Summary by Futu AI
On March 28, 2024, Vivos Therapeutics, Inc., a medical technology company specializing in treatments for sleep-related breathing disorders, announced its financial results for the fourth quarter and fiscal year ended December 31, 2023. The company reported a decrease in revenue to $3.2 million for the fourth quarter and $13.8 million for the full year, compared to the previous year's figures of $4.0 million and $16.0 million, respectively. This decline was attributed to lower appliance revenue and enrollments in the Vivos Integrated Provider program, partially offset by increased revenue from home sleep testing services and seminars. Despite the revenue drop, Vivos achieved a 27% reduction in annual operating expenses due to cost-cutting initiatives, leading to a significant reduction in net loss for both the fourth quarter and...Show More